Starting Tuesday, May 16, HM will switch from alteplase (Activase®) to tenecteplase (TNKase®) for acute ischemic stroke. When compared to alteplase, tenecteplase has similar or better efficacy and safety, with a simpler administration process.
Starting Tuesday, May 16, HM will switch from alteplase (Activase®) to tenecteplase (TNKase®) for acute ischemic
stroke. When compared to alteplase, tenecteplase has similar or better efficacy and safety, with a simpler
administration process.
Other name changes:
-
Stroke Alteplase orders now Stroke Tenecteplase orders.
-
Alteplase (tPA)-Associated Angioedema Management now Thrombolytic-Associated Angioedema Management.
-
Alteplase (tPA) Reversal Management – Symptomatic ICH Management within 24 Hours of alteplase (tPA) Administration now Thrombolytic Reversal Management – Symptomatic ICH Management within 24 Hours of Thrombolytic Administration.
The term tPA will be eliminated from all sources (e.g., Epic, Pyxis, etc.). Instead, the words tenecteplase, alteplase or
thrombolytic will be used, when applicable. This change is recommended by the Institute for Safe Medication Practices
and will also help avoid confusion.
For questions email DrugInfo@houstonmethodist.org.
